Correlation between susceptibility of Mycobacterium tuberculosis by microtiter plate Alamar blue assay and clinical outcomes

Journal of the Medical Association of Thailand

Volumn 85, Issue 7, 2002, Pages 820-824

  Sungkanuparph, Somnuek ^a   Pracharktam, Roongnapa ^a   Thakkinstian, Ammarin ^a   Buabut, Benjamas ^a   Kiatatchasai, Wiphawee ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Clinical Outcome; Correlation; Mycobacterium tuberculosis; Susceptibility; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; FEMALE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROTITER PLATE ASSAY; MYCOBACTERIUM TUBERCULOSIS; OUTCOMES RESEARCH; PREVALENCE; RELIABILITY; STRAIN DIFFERENCE; THAILAND; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BIOLOGICAL ASSAY; COLORING AGENTS; DRUG RESISTANCE; HUMANS; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT (HEALTH CARE); OXAZINES; TUBERCULOSIS; XANTHENES;

EID: 14244272774     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Palwatwichai A. Tuberculosis in Thailand. Respirology 2001; 6: 65-70.
2. Maranetra KN. Treatment of multidrug-resistant tuberculosis in Thailand. Chemotherapy 1996; 42 (Suppl3): S10-15.
3. Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for highthroughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997; 41: 1004-9.
4. Franzblau SG, Witzig RS, McLaughlin JC, et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol 1998; 36: 362-6.
5. Palomino JC, Portaels F. Simple procedure for drug susceptibility testing of Mycobacterium tuberculosis using a commercial colorimetic assay. Eur J Clin Microbiol Infect Dis 1999; 18: 380-3.
6. StataCorp 2001. Stata Statistical Software: Release 7.0. College Station, TX: Stata Corporation.
7. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: Treatment outcomes in 6 countries. JAMA 2000; 283: 2537-45.
8. Kassim S, Sassan-Morokro M, Ackah A, et al. Two-year follow-up of persons with HIV-1 and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995; 9: 1185-91.
9. Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Resp Crit Care Med 1996; 154: 1034-8.
10. EI-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis 1998; 26: 1148-58.
11. Sterling TR, Alwood K, Gachuhi R, et al. Relapse rates after short-course (6 month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999; 13: 1899-904.
12. Eltringham IJ, Drobniewski F. Multiple drug resistant tuberculosis: Aetiology, diagnosis and outcome. Br Med Bull 1998; 54: 569-78.
13. Flament SM, Robert J, Jarlier V, Grosset J. Outcome of multi-drug-resistant tuberculosis in France: A nationwide case-control study. Am J Respir Crit Care Med 1999; 160: 587-93.